Valeants posts delayed earnings and names new people to its board

Valeant Pharmaceuticals has filed its long-overdue financial report for 2015, plus restated results for several quarters, resolving its default on some of its $30 billion in debt and averting other problems.

The filings with the U.S. Securities and Exchange Commission confirm that the Canadian drugmaker was aggressive not just in hiking prices of older medicines, but also in stating revenue prematurely.

The restatement reduced previously reported fiscal 2014 revenue by about $58 million, net income attributable to its shareholders by about $33 million, and earnings per share by 9 cents.

The restatement for the first quarter of 2015 lowered revenue by about $21 million, but increased net income attributable to Valeant by about $24 million and earnings per share by 7 cents.

The financial reports resolve just one of Valeant's troubles, which include having several executives grilled by Congress Wednesday on Valeant's strategy of jacking up prices of medicines many times prior levels.

Valeant is dealing with three federal probes into its accounting and business practices, a huge stock plunge and insurers demanding bigger discounts from its inflated drug list prices, as activist investor Bill Ackman and others attempt a turnaround.

The company also announced on Friday that seven members of its board of directors will not stand for re-election. One of the people taking their place will be new CEO Joe Papa, who was named to replace Mike Pearson last week.

Let's block ads! (Why?)

Share on Google Plus

About Văn Khang Nguyễn

My blog is the place to update the latest information on sports, science and technology ... If you found this article good, useful please the share for others to see, even if you want to design a ecommerce website or web edit or set a special plugin functionality, please contact us now (Information in the footer)
    Blogger Comment
    Facebook Comment

0 nhận xét:

Đăng nhận xét